Karin Purshouse
YOU?
Author Swipe
View article: Figure S2 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
Figure S2 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers Open
Supplementary Figure S2 shows simulation results of clonogenic assays under copy number-dependent and -independent cell fitness
View article: Table S1 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
Table S1 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers Open
Supplementary Table S1 contains FISH proteomics datasets
View article: Figure S1 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
Figure S1 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers Open
Supplementary Figure S1 characterises the MYCN amplification status, copy number heterogeneity and growth behaviour in neuroblastoma samples
View article: Figure S6 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
Figure S6 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers Open
Supplementary Figure S6 shows copy number dynamics in EGFR-amplified glioblastoma samples
View article: Table S2 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
Table S2 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers Open
Supplementary Table S2 lists the GDCS compounds used in Supplementary Figure S4L
View article: Figure S4 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
Figure S4 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers Open
Supplementary Figure S4 provides computational and experimental models of ecDNA-dependent treatment responses in neuroblastoma
View article: Figure S7 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
Figure S7 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers Open
Supplementary Figure S7 demonstrates the impact of MYCN dosage on treatment response in neuroblastoma
View article: Figure S3 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
Figure S3 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers Open
Supplementary Figure S3 demonstrates how MYC(N) dosage differences drive phenotypic heterogeneity in ecDNA-containing cancers
View article: Data from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
Data from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers Open
Extrachromosomal DNA (ecDNA) amplification enhances intercellular oncogene dosage variability and accelerates tumor evolution by violating foundational principles of genetic inheritance through its asymmetric mitotic segregation. Spotlight…
View article: Table S4 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
Table S4 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers Open
Supplementary Table S4 contains information about the MYCN status of neuroblastoma patient samples used in Figure 1 and Supplementary Figure 1
View article: Figure S5 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
Figure S5 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers Open
Supplementary Figure S5 shows copy number dynamics in ecDNA vs. HSR neuroblastoma cells in response to cytotoxic and targeted therapies
View article: Figure S8 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
Figure S8 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers Open
Supplementary Figure S8 illustrates how one-two punch, senolytic therapies can be used to target tumor cells with low MYCN copy numbers
View article: Table S3 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
Table S3 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers Open
Supplementary Table S3 contains information about the MYCN and TP53 status of cell lines used in Supplementary Figure S4L
View article: TOURISM study (Treatment Outcomes in UteRIne SarcoMa): a 10-year retrospective evaluation of practice in the UK
TOURISM study (Treatment Outcomes in UteRIne SarcoMa): a 10-year retrospective evaluation of practice in the UK Open
Background Although rare, uterine sarcomas account for a high proportion of uterine cancer mortality. Treatment options and robust trial data are limited. Objectives The TOURISM study (Treatment Outcomes in UteRIne SarcoMa) is a UK-wide st…
View article: Imaging extrachromosomal DNA (ecDNA) in cancer
Imaging extrachromosomal DNA (ecDNA) in cancer Open
Extrachromosomal DNA (ecDNA) are circular regions of DNA that are found in many cancers. They are an important means of oncogene amplification, and correlate with treatment resistance and poor prognosis. Consequently, there is great intere…
View article: Adult brain tumour research in 2024: Status, challenges and recommendations
Adult brain tumour research in 2024: Status, challenges and recommendations Open
In 2015, a groundswell of brain tumour patient, carer and charity activism compelled the UK Minister for Life Sciences to form a brain tumour research task and finish group. This resulted, in 2018, with the UK government pledging £20m of f…
View article: The Scottish COVID Cancer Immunity Prevalence Study: A Longitudinal Study of SARS-CoV-2 Immune Response in Patients Receiving Anti–Cancer Treatment
The Scottish COVID Cancer Immunity Prevalence Study: A Longitudinal Study of SARS-CoV-2 Immune Response in Patients Receiving Anti–Cancer Treatment Open
Background Cancer and anti-cancer treatment (ACT) may be risk factors for severe SARS-CoV-2 infection and limited vaccine efficacy. Long–term longitudinal studies are needed to evaluate these risks. The Scottish COVID cancer immunity preva…
View article: PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non‐muscle‐invasive bladder cancer
PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non‐muscle‐invasive bladder cancer Open
Objectives This study aimed to investigate the anti‐PD‐1 inhibitor pembrolizumab as a potential agent for use in non‐muscle‐invasive bladder cancer (NMIBC) by conducting a Phase 1 safety run‐in study to assess the safety and tolerability o…
View article: Oncogene expression from extrachromosomal DNA is driven by copy number amplification and does not require spatial clustering in glioblastoma stem cells
Oncogene expression from extrachromosomal DNA is driven by copy number amplification and does not require spatial clustering in glioblastoma stem cells Open
Extrachromosomal DNA (ecDNA) are frequently observed in human cancers and are responsible for high levels of oncogene expression. In glioblastoma (GBM), ecDNA copy number correlates with poor prognosis. It is hypothesized that their copy n…
View article: Author response: Oncogene expression from extrachromosomal DNA is driven by copy number amplification and does not require spatial clustering in glioblastoma stem cells
Author response: Oncogene expression from extrachromosomal DNA is driven by copy number amplification and does not require spatial clustering in glioblastoma stem cells Open
Article Figures and data Abstract Editor's evaluation Introduction Results Discussion Materials and methods Data availability References Decision letter Author response Article and author information Metrics Abstract Extrachromosomal DNA (…
View article: Scottish COVID CAncer iMmunity Prevalence (SCCAMP) - a longitudinal study of patients with cancer receiving active anti-cancer treatment during the COVID-19 pandemic
Scottish COVID CAncer iMmunity Prevalence (SCCAMP) - a longitudinal study of patients with cancer receiving active anti-cancer treatment during the COVID-19 pandemic Open
Background Cancer and systemic anti-cancer treatment (SACT) have been identified as possible risk factors for infection and related severe illness associated with SARS-CoV-2 virus as a consequence of immune suppression. The Scottish COVID …
View article: Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19
Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19 Open
The findings of this study of patients with active cancer suggest that recent SACT is not associated with inferior outcomes from COVID-19 infection. This has relevance for the care of patients with cancer requiring treatment, particularly …
View article: Oncogene expression from extrachromosomal DNA is driven by copy number amplification and does not require spatial clustering
Oncogene expression from extrachromosomal DNA is driven by copy number amplification and does not require spatial clustering Open
Summary Extrachromosomal DNA (ecDNA) are frequently observed in human cancers and are responsible for high levels of oncogene expression. In glioblastoma (GBM), ecDNA copy number correlates with poor prognosis. It is hypothesized that thei…
View article: Extra-chromosomal DNA (ecDNA) do not necessarily cluster or interact with condensates in glioblastoma stem cells
Extra-chromosomal DNA (ecDNA) do not necessarily cluster or interact with condensates in glioblastoma stem cells Open
View article: Scottish COVID Cancer Immunity Prevalence (SCCAMP) - a Longitudinal Study of Patients with Cancer Receiving Active Anti-Cancer Treatment During the COVID-19 Pandemic
Scottish COVID Cancer Immunity Prevalence (SCCAMP) - a Longitudinal Study of Patients with Cancer Receiving Active Anti-Cancer Treatment During the COVID-19 Pandemic Open
View article: Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID‐19: disease control as an important factor relative to recent chemotherapy or anti‐CD20 therapy
Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID‐19: disease control as an important factor relative to recent chemotherapy or anti‐CD20 therapy Open
Summary Patients with haematological malignancies have a high risk of severe infection and death from SARS‐CoV‐2. In this prospective observational study, we investigated the impact of cancer type, disease activity, and treatment in 877 un…
View article: Characterisation and outcomes of patients referred to a regional cancer of unknown primary team: a 10-year analysis
Characterisation and outcomes of patients referred to a regional cancer of unknown primary team: a 10-year analysis Open
View article: COVID-19 and cancer registries: learning from the first peak of the SARS-CoV-2 pandemic
COVID-19 and cancer registries: learning from the first peak of the SARS-CoV-2 pandemic Open
View article: MA10.10 Lung Cancer Admission Rates During the COVID-19 Pandemic to a Tertiary Cancer Centre in South East Scotland.
MA10.10 Lung Cancer Admission Rates During the COVID-19 Pandemic to a Tertiary Cancer Centre in South East Scotland. Open
View article: 1703P UK Coronavirus Cancer Monitoring Project (UKCCMP): A national reporting network for real time data of the COVID-19 pandemic
1703P UK Coronavirus Cancer Monitoring Project (UKCCMP): A national reporting network for real time data of the COVID-19 pandemic Open